Program

 “Health Care Technological Innovation – From Idea to Commercialization”
The 14th Course

An Executive Program for Biotechnology, Medical Device and Health IT Entrepreneurs and Managers

December 5th-8th, 2021 – Sunday through Wednesday, Tel Aviv, Israel

 *The following Agenda is subject to changes*

  • Day 1
  • Day 2
  • Day 3
  • Day 4

Sunday, December 5th, 2021

Day’s Theme: The Creative Process and Technology Assessment

8:30 – 9:00 AM

Registration/Administrative & Continental Breakfast

9:00 – 9:20 AM

Welcome and Opening Remarks:

Prof. Moshe Zviran, Dean, Coller School of Management, Tel Aviv University

Course Directors:

Introduction to Program Structure, Faculty and Participants Introduction
Benny Zeevi, M.D. Managing General Partner, Tel Aviv Venture Partners & Run Young Capital

9:20 – 10:10 AM

Session 1: Keynote Lecture
The New “Kids” on the Block: Microbiome – Case study, what can we learn?

Mike Berman, medical device investor/entrepreneur, past President of the Cardiology business of Boston Scientific

10:10 – 11:00 AM

Session 2: The Persuasive Pitch, Part 1: Introduction of course participants

Moderators:

Benny Zeevi, M.D. Managing General Partner, Tel Aviv Venture Partners & Run Young Capital

Susan Alpert M.D., PhD, Principal SFADC LLC, Chief Regulatory Officer, SynerFuse, Inc

Mike Berman, Medical device Investor/Entrepreneur, Past President Cardiology Business, Boston Scientific

In order to give participants a chance to learn more about their colleagues in the course, and as the first part of our focus on presentations, we are asking each participant to prepare and deliver a 3 minute presentation, using 4-5 power point slides, to introduce himself and his/her company to the group

11:00 – 11:20 AM

Coffee Break

11:20 – 1:00 PM

Session 3: The Persuasive Pitch, Part 2: Introduction of course participants

1:00 – 2:00 PM

Networking Lunch

2:00 – 2:45 PM

Session 4: Project, Product or Company?: Assessment and Qualification of Technologies as a Basis for a Startup

Healthcare (Medicine) has to actively adopt Innovation in its teaching and culture, rather than letting it occur passively. Innovation is needed to overcome the many unmet needs that exist in Healthcare (Medicine) today
The successful translation of discoveries from the lab to the market is the greatest challenge facing an entrepreneur. Many companies are formed on technologies emanating from university laboratories and spinouts from major corporations as well as new ideas originating by life science companies ventures. One has to define what is the objective vs. what is possible in the healthcare market. Many healthcare innovations fall because they neither integrate with existing clinical practice nor are successful in creating new ones. This session will provide tools and a contextual framework as to how technologies can be assessed by founders, corporations and VCs so that they can orient and characterize their business for capitalization and partnering.

Moderator: Benny Zeevi, M.D. Managing General Partner, Tel Aviv Venture Partners Evan Norton, Divisional Vice President, Abbott Ventures

2:45 – 3:45 PM

Session 5: Market Analysis and Competitive Analysis – Essentials of Marketing in life Sciences Companies

This session will focus on Market analysis, Clinical state of the art and product positioning: assessment of different applications for the same product (choosing the right application from commercial point of view), Determination of subgroup of patients most appropriate for the product, Competitive analysis, Importance of opinion leaders, patients groups, patients organization and  Selling strategy: To build mutually satisfying long-term relationships with key customers in order to acquire and retain their business.

Competitive analysis — product differentiation linked to improvements in efficiency and effectiveness – can help potential customers’ better grasp the implication of economic value for their own businesses.  Economic value to the customer analyses are calculated as cost savings, improvements in long-term client retention, decreased speed in client acquisition, increased average revenue/customer, and revenue associated with the opportunity/ability to establish entry barriers.  Often times, making these explicit links from the market and competitive data can lead to powerful insights as to the value of the offering to the customer, and help make a transformative difference in outcome.

Moderator:
Benny Zeevi, M.D. Managing General Partner, Tel Aviv Venture Partners & Run Young Capital
Yael Nir, MD, Consulting, Spring Consulting

3:45 – 4:00 PM

Coffee Break

4:00 – 5:00 PM

Session 6: Keynote Lecture TBD

5:00 – 6:00 PM

Session 7: Intellectual Capital Management

The goal of the session is to provide information and insight into the specific issues confronting investigators, entrepreneurs, investors, and their patent attorneys. The session will address the formation of specific IP strategy and execution and using intellectual capital for competitive advantage. Content includes major issues confronting companies with US and filings in other jurisdictions related to biotechnology, e.g., patent ownership, non-obviousness rulings, the scope of what can be patented. A VC will also provide an investor viewpoint.

Lecture and Discussion: Brian Hopkins, Special Counsel, Cooley LLP

Download program PDF
Click here for PDF

* Changes in curriculum may occur*

Monday, December 6th, 2021

Day’s Theme: Strategy and Execution

8:30 – 9:00 AM

Continental Breakfast

9:00 – 10:00 AM

Session 8: Incorporating Reimbursement in the Company Development Strategy

Moderator:
Bob Goldberg Ph.D., Vice President, The Center for Medicine in the Public Interest

Stuart Kurlander, Healthcare and Life Sciences Partner at Latham & Watkins LLP

Mike Berman, medical device investor/entrepreneur, past President of the Cardiology business of Boston Scientific

Bob Goldberg Ph.D., Vice President CMPI, CEO Thrive HealthRx, LLC

10:00 – 10:50 AM

Session 9: The Medical Device Industry in 2021: New Imperatives

David Cassak and Stephen Levin, Managing Partners, Innovation In Medtech, LLC, Editors-in-Chief, The MedTech Strategist

10:50 – 11:30 AM

Session 10: Keynote Lecture- My Path Through Medicine, Engineering & Innovation

Prof. Elazer Edelman, Institute for Medical Engineering and Science, MIT, Cambridge, USA

11:30 – 11:50 AM

Coffee break

11:50 – 1:20 PM

Session 11: Biotechnology and Medical device Regulatory Planning, Clinical Development and the Implications for Strategy and Financing: From Proof of Concept to Marketing Success. Designing and conducting clinical trials

This session provides an abbreviated view of the overall process and specific insight into planning for FDA regulations in light of strategy, financial needs, and the concerns of prospective partners and investors. Entrepreneurs need to understand that there is an increasing need to perform clinical studies to support medical device safety and performance claims. They also need to have a basic understanding of the activities, resources and costs associated with the design and conduct of clinical studies. The failure to incorporate an effective clinical strategy into new project planning can lead to significant project and funding delays or, worse, the failure of the project. This session will provide an overview of the increasing need for device clinical study data; key activities, resource needs and costs; and planning for the successful design and conduct of medical device clinical studies for acceptance in the United States and Europe, even when these studies are conducted outside of these regulatory jurisdictions.

Faculty:

Susan Alpert, PhD, MD, Principal, SFA Consulting LLC, Former Senior Vice President, Chief Regulatory Officer of Medtronic, Former Director, Office of Device Evaluation, CDRH at the FDA

Andrew M. Weiss, President & CEO ReCor Medical – Clinical & Pre-Clinical evidence to support a medical device company, Trial Strategy and Conducting Multi-site Clinical Trials

1:20 – 2:00 PM

Networking Luncheon

2:00 – 4:20 PM

Session 12: Capitalization of a life science Venture –Value inflection Points, Milestones and Capital Requirements, Alternative financing, Terms etc. Part 1

Financing a life science venture is challenging. When meeting with investors and prospective strategic partners, entrepreneurs will often hear questions that ask: Where are you in the value chain?” How does your business model reflect this?” “How do you describe your milestones and how are you managing towards them?” How do your milestones tie-in with your value inflection points?”  This session will consist of a brief overview of typical value inflection points for each type of product, classical and alternative ways of financing, terms of financing rounds and more.

Moderator:
Benny Zeevi, M.D. Managing General Partner, Tel Aviv Venture Partners

Andrew M. Weiss, President & CEO ReCor Medical

Dr. Morris Laster, Managing Partner, OurCrowd

Allen Kamer, Managing Partner, OurCrowd Qure – From Start to Finish – Everything Entrepreneurs Need to Know to Get Your Idea Funded All the Way Through Exit

Dr. Ayal Shenhav, Head of Hi-Tech & Investment Funds Department, Gross, Kleinhendler, Hodak, Halevy, Greenberg, Shenhav & Co.

Dr. Ora Dar, Venture Consultant in Biotechnology and Biomedicine. Former head of the Life Sciences sector at Israel Innovation Authority

4:20 – 4:40 PM

Coffee Break

4:40 – 5:00 PM

Session 13: Capitalization of a life science Venture- Part 2

Robert E. “Bob” Sweeney, DA, MS, MBA, Principal & Partner and Gary Goldman DDS MD MBA, Founder and CEO of Global Health Impact Network (GHIN) and Global Health Impact Fund LLC

5:00 – 5:50 PM

Session 14:  The Persuasive Pitch, Part 2: Presenting Your Idea—and Yourself—With Purpose, Clarity, and Power

On the path from ‘idea to commercialization’ you will need to communicate persuasively about your product, your company, and yourself to a wide range of audiences—investors, regulators, partners, customers, and your own team. During this session we will focus on one of the most common—and, perhaps surprisingly, often one of the more difficult—types of presentations that entrepreneurs must deliver: the short introduction.

Barry Katz, Founder and CEO, Barry Katz Communicating Success

5:50 – 7:15 PM

Session 15: The Healthy Way to Build Your Community – Interactive Master Class for Fast Growth Life Sciences Companies.

The goal of this session is to improve the participants’ leadership skills in building a strong top team,

developing trust and leading difficult conversations, managing your networks, board engagement, managing energy for resilience and your personal brand.

Moderator: Gila Tolub, Partner, McKinsey, Tel Aviv

7:15 PM

Drive to network dinner at the Mandarin Loft – Hotel Mandarin

7:30 PM

Network Dinner for Faculty, Participants, and life sciences executives

At the Mandarin Loft – Hotel Mandarin, Yunitsman 21, Tel Aviv, Zuk Beach

Lecture by TBD

Download program PDF
Click here for PDF

* Changes in curriculum may occur*

Tuesday, December 7th, 2021

Day’s Theme: Bringing the product to the market

8:30 – 9:00 AM

Continental Breakfast

9:00 – 10:00 AM

Session 16: Keynote Lecture TBD- Lessons Learned from the Development of TAVI

Stanton Rowe, Founder & CEO NTX Biomedical

10:00 – 11:00 AM

Session 17: Biopharmaceutical and Medical Device Licensing, Partnering and Strategic Alliances

Major practical issues in formulation of partnering goals and managing different types of strategic alliances, preparation for positioning for partnering, identifying and qualifying prospective partners, making the approach, negotiation, closing the deal, with special emphasis on how to design alliances and avoid many potential problems and complications in managing this relationship.

Moderator:
Benny Zeevi, M.D. Managing General Partner, Tel Aviv Venture Partners

Orli Gal, Partner, Herzog, Fox & Neeman

11:00 – 11:20 AM

Coffee Break

11:20 – 12:00 PM

Session 18: Establishing a US Entity

John Lieberman, Perelson Weiner LLP

Carolyn Hochstadter, E.Carolyn Hochstadter, Dicker, LLC

12:00 – 1:00 PM

Session 19: Keynote Lecture – Healthcare 2030 – The Future Hospital, The Coming Transformation

Eyal Zimlichman, MD, MSc (MHCM), Deputy Director General, Chief Medical Officer and Chief Innovation and Commercialization Officer at Sheba Medical Center

1:00 – 2:00 PM

Networking Luncheon

2:00 – 3:00 PM

Session 20: TBD

3:00 – 5:30 PM

Session 21: Meet and Ask the Experts – Roundtables Mentoring

Medical Devices: Andrew M. Weiss, President & CEO ReCor Medical

Regulation: Susan Alpert, PhD, MD, Principal, SFA Consulting LLC, Former Senior Vice President, Chief Regulatory Officer of Medtronic, Former Director, Office of Device Evaluation, CDRH at the FDA

Reimbursement: Stuart Kurlander, Healthcare and Life Sciences Partner at Latham & Watkins LLP

Intellectual Property: Brian Hopkins, Special Counsel, Cooley LLP

Capitalization: Mike Berman, medical device investor/entrepreneur, past President of the Cardiology business of Boston Scientific, Dr. Morris Laster, Managing Partner, OurCrowd, Allen Kamer, Managing Partner, OurCrowd Qure, Robert E. “Bob” Sweeney, DA, MS, MBA, Principal & Partner and Gary Goldman DDS MD MBA, Founder and CEO of Global Health Impact Network (GHIN) and Global Health Impact Fund LLC

Health Tech: Paul Browne, Senior Vice President and Chief Information Officer, Henry Ford Health System, Adam Dicker, MD, PhD, FASTRO, Enterprise Senior Vice President, Professor and Chair of Enterprise Radiation Oncology

US Healthcare System: Scott Dulchavsky MD PhD, CEO, Innovation Institute at Henry Ford Health System/ Lisa Prasad, Managing Director, Global Innovations, Henry Ford Health System, Carolyn Hochstadter, E.Carolyn Hochstadter, Attorney at Law, Dicker, LLC

5:30 – 6:00 PM

Coffee Break

6:00 – 7:00 PM

Session 22: Macro trends in the USA healthcare system and their implications for inventors, entrepreneurs and investors.

Keynote Lecture: Ezekiel “Zeke” J. Emanuel, Vice Provost for Global Initiatives, the Diane v.S. Levy and Robert M. Levy University Professor, and Co-Director of the Healthcare Transformation Institute at the University of Pennsylvania

Download program PDF
Click here for PDF

* Changes in curriculum may occur*

Wednesday, December 8th, 2021

Day’s Theme- Health Care IT / Digital Health

8:30 – 9:00 AM

Continental Breakfast

9:00 – 10:15 AM

Session 23: Keynote lecture – “The Collision of Med Tech with Info Tech”…accessing, programing and receiving health from the palm

Peter J. Fitzgerald, MD, PhD, FACC, Professor Emeritus, Medicine & Engineering, Director, Center for Cardiovascular Technology, Stanford University, Co-founder, Managing Partner, Triventures

10:15 – 11:30 AM

Session 24: Health TechHealthcare IT and Digital Health- Part I

Health Tech – Healthcare IT and Digital health are integral technologies in healthcare and got a huge boost during the COVID-19 pandemic. For vast adoption, health tech has to prove value, meaning a better outcome in a cost-effective way.

Digital health technologies are facilitating fundamental shifts in healthcare; cultural and behavioral changes from all healthcare stakeholders, enhancing outcomes and quality of care and eventually will band the cost curve.

The potential applications of HCIT technologies and digital health, it’s role in global health, new business models, the use of social media by pharma and medical device companies as well as by healthcare providers and insurance companies and regulatory issues will be discussed.

Benny Zeevi, M.D. Managing General Partner, Tel Aviv Venture Partners – The Opportunities and Challenges of Digital Health

Paul Browne, Senior Vice President and Chief Information Officer, Henry Ford Health System

11:30 – 11:50 AM

Coffee Break

11:50 – 1:30 PM

Session 24 (Continue): Healthcare IT and Health Tech- Part 2

Michal Rosen-Zvi, Ph.D, Director for Healthcare Informatics at IBM Research- Opportunities and Challenges in Healthcare Big Data and AI

Scott Dulchavsky MD PhD, CEO, Innovation Institute at Henry Ford Health System/ Lisa Prasad, Managing Director, Global Innovations, Henry Ford Health System

Susan Alpert, PhD, MD, Former Senior Vice President, Chief Regulatory Officer of Medtronic, Former Vice President of Regulatory Sciences for C.R. Bard, Inc., previously worked at FDA.

Are Digital and Mobile Health Tools Medical Devices? Who’s Opinion Counts?

Tamara Mansfeld, Global Innovation Lead, Pfizer Corporate Strategy & Innovation- Pharma perspectives on Digital Health

1:30 – 2:30 PM

Networking Luncheon

2:30 – 4:30 PM

Session 24 (Continue): Healthcare IT and Connected Health – Part 3

Adam Dicker, MD, PhD, FASTRO, Enterprise Senior Vice President, Professor and Chair of Enterprise Radiation Oncology, Sidney Kimmel Cancer Center, Sidney Kimmel Medical College, Thomas Jefferson University- Clinical validation in digital health and how to develop collaboration with health care systems and approaches for

Hadas Bitran, Principal Group Manager Microsoft Health ILDC, Microsoft

4:30 – 6:00 PM

Session 25: The Persuasive Pitch, Part 3: Presentations Workshop

Moderator:
Benny Zeevi, M.D. Managing General Partner, Tel Aviv Venture Partners

Mike Berman, medical device investor/entrepreneur, past President of the Cardiology business of Boston Scientific

Bob Goldberg Ph.D., Vice President CMPI, CEO Thrive HealthRx, LLC

6:00 – 6:30 PM

Program Adjournment
Session 26: Teams gather for “Take-aways Exercise”

Each participant will receive at registration a worksheet to record for each session one major lesson or “take-away.”

Download program PDF
Click here for PDF

* Changes in curriculum may occur*

Contact Us

Contact
Skip to content